![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/09/shutterstock_2256286005-e1725983249730.jpg)
T-cell targeting Candid Therapeutics launches with $370m
T cell engager (TCE) startup Candid Therapeutics has debuted with $370m in its pocket to develop antibody drugs for inflammatory diseases. Candid plans to develop T cell engager antibodies to selectively target and deplete specific B lymphocyte …